ENLIVEN THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Increase (Decrease) in Accounts Payable of -$2.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.50M, a 290.37% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$519.00K, a 335.91% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $828.00K, a 156.35% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.02M.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was $817.00K, a 0.86% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was $810.00K.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was -$2.25M, a 647.45% decline from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was $411.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.02M 10-Q · filed 2026-08-05 | -$1.19M derived: sum of 3 quarters · filed 2026-08-05 | -$2.21M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$519.00K 10-Q · filed 2026-05-07 | $309.00K derived: sum of 2 quarters · filed 2026-05-07 | -$711.00K derived: sum of 3 quarters · filed 2026-05-07 | $78.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $828.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$192.00K derived: sum of 2 quarters · filed 2026-03-03 | $597.00K derived: sum of 3 quarters · filed 2026-08-05 | $817.00K 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$231.00K derived: sum of 2 quarters · filed 2026-08-05 | -$11.00K 10-Q · filed 2025-11-12 | $312.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $789.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.01M 10-Q · filed 2026-08-05 | $1.33M derived: sum of 3 quarters · filed 2026-08-05 | $1.27M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $220.00K 10-Q · filed 2026-05-07 | $543.00K derived: sum of 2 quarters · filed 2026-05-07 | $479.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.13M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $259.00K derived: sum of 2 quarters · filed 2026-03-03 | -$1.34M derived: sum of 3 quarters · filed 2026-03-03 | $810.00K 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | -$64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.67M derived: sum of 2 quarters · filed 2025-11-12 | $487.00K 10-Q · filed 2025-11-12 | -$474.00K derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $551.00K 10-Q · filed 2025-08-13 | -$410.00K derived: sum of 3 quarters · filed 2025-08-13 | -$2.00M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $2.15M 10-Q · filed 2025-05-14 | $1.19M derived: sum of 2 quarters · filed 2025-05-14 | -$399.00K derived: sum of 3 quarters · filed 2025-05-14 | -$587.00K derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$961.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$2.55M derived: sum of 2 quarters · filed 2025-03-13 | -$2.74M derived: sum of 3 quarters · filed 2025-03-13 | -$2.25M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.78M derived: sum of 2 quarters · filed 2024-11-13 | -$1.29M 10-Q · filed 2024-11-13 | -$1.27M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $304.00K 10-Q · filed 2024-08-13 | $322.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.68M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $492.00K 10-Q · filed 2024-05-14 | $510.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.87M derived: sum of 3 quarters · filed 2024-05-14 | $2.46M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.38M derived: sum of 2 quarters · filed 2024-03-14 | $1.97M derived: sum of 3 quarters · filed 2024-03-14 | $411.00K 10-K · filed 2024-03-14 | -$2.21M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.95M derived: sum of 2 quarters · filed 2023-11-09 | $393.00K 10-Q · filed 2023-11-09 | -$1.59M 10-Q · filed 2022-10-25 | $1.62M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $592.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$965.00K 10-Q · filed 2023-08-10 | -$1.23M 10-Q · filed 2022-08-03 | $264.00K derived: sum of 3 quarters · filed 2023-08-10 | $114.00K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$1.56M 10-Q · filed 2023-05-11 | -$476.00K 10-Q · filed 2022-05-06 | -$328.00K derived: sum of 2 quarters · filed 2023-06-23 | -$478.00K derived: sum of 3 quarters · filed 2023-06-23 | -$853.00K derived: sum of 4 quarters · filed 2023-06-23 | |||
| 2021-12-31 | $1.23M derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | $1.08M derived: sum of 2 quarters · filed 2023-06-23 | $704.00K derived: sum of 3 quarters · filed 2023-06-23 | $1.73M 8-K · filed 2023-06-23 | $389.00K 10-K · filed 2022-03-15 | |||
| 2021-09-30 | -$150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$525.00K derived: sum of 2 quarters · filed 2022-10-25 | $505.00K 10-Q · filed 2022-10-25 | $590.00K derived: sum of 4 quarters · filed 2022-10-25 | ||||
| 2021-06-30 | -$375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $655.00K 10-Q · filed 2022-08-03 | $740.00K derived: sum of 3 quarters · filed 2022-08-03 | $1.08M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $1.03M 10-Q · filed 2022-05-06 | $1.11M derived: sum of 2 quarters · filed 2022-05-06 | $1.46M derived: sum of 3 quarters · filed 2022-05-06 | $1.16M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $425.00K derived: sum of 2 quarters · filed 2022-03-15 | $134.00K derived: sum of 3 quarters · filed 2022-03-15 | $313.00K 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $340.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $49.00K derived: sum of 2 quarters · filed 2021-11-09 | $228.00K 10-Q · filed 2021-11-09 | -$611.00K derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | -$291.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$112.00K 10-Q · filed 2021-08-06 | -$951.00K derived: sum of 3 quarters · filed 2021-08-06 | -$126.00K derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $179.00K 10-Q · filed 2021-05-11 | -$660.00K derived: sum of 2 quarters · filed 2021-05-11 | $165.00K derived: sum of 3 quarters · filed 2021-05-11 | -$2.00K derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | -$839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | -$14.00K derived: sum of 2 quarters · filed 2021-03-05 | -$181.00K derived: sum of 3 quarters · filed 2021-03-05 | $750.00K 10-K · filed 2021-03-05 | ||||
| 2019-09-30 | $825.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $658.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.59M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | -$167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $764.00K 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $931.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |